<DOC>
	<DOCNO>NCT01402336</DOCNO>
	<brief_summary>GnRH ( Gonadotropin-releasing hormone ) antagonists IVF ( vitro fertilization ) accomplish several randomize control trial compare conventional GnRH agonist long protocol polycystic ovary syndrome ( PCOS ) patient . Moreover , debate issue refer time GnRH antagonist initiation . The purpose study investigate laboratory clinical priority ovarian stimulation IVF patient PCOS treat three different protocol .</brief_summary>
	<brief_title>GnRH Antagonist Versus GnRH Agonist Polycystic Ovary Syndrome During Vitro Fertilization - Embryo Transfer</brief_title>
	<detailed_description>GnRH Antagonist Started Stimulation Day 1 GnRH Antagonist Started Stimulation Day 6 Conventional GnRH Agonist Long Protocol</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<criteria>PCOS patient ( diagnosed 2003 ASRM ( The American Society Reproductive Medicine ) /ESHRE ( The European Society Human Reproduction Embryology ) consensus meeting guideline ) age 2040 year patient normal uterus patient abnormal thyroid function patient abnormal prolactin test patient diabetes , Cushing 's syndrome , congenital adrenal hyperplasia , androgenproducing tumor . Patients reject informed consent patient experience adverse event GnRH agonist , antagonist , recombinant FSH ( folliclestimulating hormone ) .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Polycystic ovary syndrome</keyword>
	<keyword>ovulation induction</keyword>
	<keyword>In vitro fertilization-embryo transfer</keyword>
</DOC>